diacylglycerol; polyol pathway; collagen IV; reactive oxygen species; endothelin-1 KIDNEY DISEASE ASSOCIATED with diabetes is the leading cause of chronic renal insufficiency in North America (69) . Clinical trials have demonstrated that high glucose is the principal cause of renal damage in both type 1 (12) and 2 diabetes (68) . Although the underlying genetic predisposition to this microvascular complication remains elusive (53) , investigation of cellular and molecular mechanisms has identified an integrated group of signaling and gene expression systems triggered directly or indirectly by high glucose (65) . Altered mesangial cell function in high glucose is central to the pathogenesis of progressive diabetic glomerulopathy. Progressive accumulation of mesangial matrix due to increased synthesis and decreased degradation of mesangial extracellular matrix proteins, including collagen IV (1, 42, 59 ) and fibronectin (49) , ultimately obliterates the glomerular capillary loops, leading to renal failure. In the diabetic milieu, mesangial cells are transformed into a sclerotic phenotype by the direct effects of high glucose (4), including enhanced expression of autocrine growth factors (54) , and by intraglomerular hypertension caused by highglucose-induced loss of afferent arteriolar contractility (73) . In the search for the cellular mechanisms of diabetic complications, a pivotal role for protein kinase C (PKC) is recognized in every cell type targeted by the toxic effects of high glucose (45) . The following describes high-glucoseinduced activation of mesangial cell PKC as a major contributor to the initiation and propagation of diabetic glomerulosclerosis.
EXPRESSION OF MESANGIAL CELL ISOZYMES
The PKC family of at least 12 isozymes is classified into conventional PKC-␣, -␤ I , -␤ II , and -␥, which re-quire Ca 2ϩ and are activated by diacylglycerol (DAG) or phorbol ester; novel PKC-␦, -⑀, -, and -, which are Ca 2ϩ independent and activated by DAG or phorbol ester (60) ; and atypical PKC-and -, which are neither Ca 2ϩ nor DAG sensitive (75) . The expression pattern and response of specific PKC isozymes to growth factors confer unique cellular phenotypic characteristics, including differentiation during development, maintenance of a normal differentiated state (32, 56) , or generation of an abnormal phenotype in response to pathogenic stimuli, e.g., high glucose. The function of individual PKC isozymes is likely conferred, in part, by their subcellular localization and binding to specific anchoring proteins after activation and translocation (9, 46) . Furthermore, differences in the individual domain structure of the PKC isozymes allows for the identification of pharmacological agents that have isozyme-selective modulation (30, 70) .
In cultured mesangial cells, expression of PKC-␣, -␤ I , -␤ II , -␦, -⑀, and -has been reported by most investigators (2, 6, 26, 33, 36, 55) . Koya et al. (39) confirmed the detection of PKC-␤ I in both cultured mesangial cells and isolated glomeruli, although they reported that PKC-␤ II expression was less abundant. We have consistently demonstrated the presence of PKC-␣, -␤ II , -␦, -⑀, and -in glomeruli isolated from normal and streptozotocin (STZ)-induced diabetic rats (5) and the identical expression of the same PKC isozymes, as well as PKC-␤ I , in primary cultured rat mesangial cells (11, 18, 31, 36) . Using immunogold labeling of normal and STZ-diabetic rat glomeruli examined by transmission electron microscopy, we have identified that mesangial, visceral epithelial, and endothelial cells all express PKC-␣, -␤ II , -␦, and -⑀ (5).
ALTERED RESPONSE OF MESANGIAL CELL-SPECIFIC PKC ISOZYMES IN HIGH GLUCOSE
The effects of high glucose on glomerular cell PKC isozyme expression and activity have been identified using animal models of diabetes and in cultured cells. Kikkawa et al. (37) were the first to report increased mesangial cell membrane content of PKC-␣ and -after 3 and 5 days of high-glucose exposure, taken as evidence of translocation and probable activation of these isozymes. In primary cultured rat and human mesangial cells, Koya et al. (39) detected increased cell membrane PKC-␣ and -␤ I after 4 days of high glucose. After exposure of primary cultured rat mesangial cells to 30 mM glucose, our laboratory has observed that total cellular PKC-␦ is significantly increased at 24 h (13) and total PKC-␣, -␤ II , and -⑀ are increased by 48 h (36). These findings indicate enhanced expression or decreased degradation of these particular isozymes in high glucose. Immunoblotting of mesangial cellular fractions revealed increased membrane and nuclear PKC-␣, -␦, and -⑀ after 48 h in 30 mM glucose (36) and enhanced recovery of membrane-associated PKC-as early as 24 h of high-glucose exposure (13) . Under the same conditions, we observed by confocal immunofluorescence imaging a high-glucose-induced pattern of mesangial cell PKC -␣, -␤ II , -␦, and -⑀ translocation characterized by enhanced fluorescence labeling of the plasma membrane, the nucleus (including nuclear membrane), and, possibly, cytoskeletal elements (36, 76) . By immunoblotting the cytosolic and membrane cellular fractions of glomeruli isolated from the STZdiabetic rat, we and others have demonstrated increased membrane recovery of PKC-␣, -␦, and -⑀, suggesting an activation/translocation pattern of these PKC isozymes in the diabetic milieu (5, 24, 37, 39) .
Many laboratories have identified increased total PKC activity in both glomeruli from STZ-diabetic rats (10, 39, 61) and primary mesangial cells cultured in high glucose (4, 8, 11, 25, 36) by analyzing PKC-specific substrate phosphorylation in total cell lysates or cellular fractions. Recently, our laboratory reported increased PKC-␦ and -activity in primary rat mesangial cells exposed to high glucose for 24 h, as analyzed by immunoprecipitating these isozymes from total cell lysate or membrane fractions and measuring phosphorylation of isozyme-specific substrates. This approach enables a more sensitive and specific detection of the activity of individual PKC isozymes. The exact mechanisms whereby mesangial cell PKC isozymes appear to be sequentially activated in high glucose over 24-48 h remain to be elucidated.
HOW DOES HIGH GLUCOSE CAUSE MESANGIAL CELL PKC ACTIVATION?
Entry of glucose into mesangial cells through GLUT1 transport raises the intracellular concentration of glucose, reflecting the hyperglycemic state (28, 29) . Entry of excess glucose into intermediate metabolic pathways stimulates interactive signaling mechanisms, which directly or indirectly activate PKC isozymes. The following describes the roles of the polyol pathway and the generation of reactive oxygen species contributing to the enhanced responsiveness of mesangial cell PKC isozymes in high glucose.
The Polyol Pathway
The polyol pathway converts glucose to sorbitol and, subsequently, fructose, generating an increased ratio of NADH/NAD ϩ (64). This change in redox potential drives conversion of glycolytic triose phosphate intermediates, produced during glycolysis or metabolism through the pentose phosphate pathway, into the second messengers phosphatidic acid and DAG. De novo synthesized DAG may directly activate conventional and novel PKC isozymes, whereas phosphatidic acid may activate PKC- (43) . In cultured mesangial cells, aldose reductase inhibition prevents the accumulation of membrane-associated DAG observed within 24 h of exposure to high glucose (11) and also prevents the translocation pattern of PKC-␦ and -⑀ caused by 48 h of high glucose (36) . By contrast, in the same mesangial cell preparation, two different aldose reductase inhibitors failed to prevent high-glucose-enhanced translocation of PKC-␣ and -␤ (36) . These data are in keeping with high-glucose-induced activation of PKC-␣ and -␤ by a mechanism(s) that is independent of the polyol pathway.
In diabetic animal models and human studies where aldose reductase inhibitors were used to treat or prevent diabetic nephropathy, the outcomes remain controversial (44, 50, 51, 52) . We have demonstrated that treatment of STZ-diabetic rats with tolrestat prevents glomerular hyperfiltration, glomerular hypertrophy, and increased microalbuminuria but does not prevent fractional mesangial expansion in the first 12 wk of diabetes (15) . Our results indicate that the polyol pathway may be linked to some, but not all, mechanisms of diabetes-induced early progressive glomerulosclerosis in this model. The finding of increased aldose reductase mRNA in the peripheral blood mononuclear cells of human subjects with type 1 diabetes and nephropathy, compared with levels of mRNA in age-and diabetesduration-matched subjects without nephropathy or in nondiabetic controls, suggests that upregulation of aldose reductase expression is associated with an increased risk for nephropathy (58) .
Another potential action of aldose reductase is to detoxify dicarbonyls, such as methylglyoxal and 3-deoxyglucosone, and lipid dialdehydes generated in excess by raised intracellular glucose (16) . Hence, the role of the polyol pathway, and in particular the contribution of aldose reductase activity, to the pathogenesis of diabetic nephropathy is complex. Further studies are needed to identify the independent contributions to, and relative importance of, the polyol pathway to individual PKC isozyme activation and to the detoxification of dicarbonyls.
Reactive Oxygen Species
Reactive oxygen species, such as hydrogen peroxide (H 2 O 2 ), superoxide anion, and hydroxyl radical, are generated during oxidative stress and implicated in the mechanisms of diabetic nephropathy (47, 48) . Excess glucose metabolism, including oxidation, is required for mesangial cell generation of reactive oxygen species in the diabetic milieu (22) . During conversion of glucose to sorbitol, the NADP ϩ /NADPH ratio is increased and causes glutathione depletion and accumulation of reactive oxygen species (41) . In many cell types, reactive oxygen species are generated as second messengers during signal transduction by agonists implicated in microvascular complications of diabetes, e.g., angiotensin II (20), platelet-derived growth factor (63) , and advanced glycation end products (AGE) (72) . The role of reactive oxygen species in mediating the effects of high glucose is inferred by the efficacy of antioxidants in preventing phenotypic changes in cultured mesangial cells, e.g., increased transforming growth factor (TGF)-␤ 1 and collagen production (62, 66) and early progressive diabetic nephropathy in the STZ-diabetic rat (23, 40) . Collagen production in cultured mesangial cells exposed to high glucose is prevented by taurine (67) 
or vitamin E (66).
Evidence is mounting for a mechanistic link between the generation of reactive oxygen species and consequent activation of mesangial cell PKC isozymes in high glucose (21) . Ha and Lee (22) reported that in cultured rat mesangial cells, high glucose generates H 2 O 2 within 1 h and inhibition of PKC blocks highglucose-or H 2 O 2 -induced TGF-␤ 1 and fibronectin mRNA expression and protein synthesis. These findings suggest that reactive oxygen species produced in high glucose directly or indirectly stimulate PKC. One mechanism for direct activation by reactive oxygen species is through redox changes in sulfhydryl groups on PKC isozyme cysteine-rich regions. These redox changes may also render individual PKC isozymes more responsive to DAG activation during signal transduction (19) . Taken together, these data support a role for high-glucose activation of PKC and subsequent matrix protein expression through reactive oxygen species-dependent pathways.
OUTCOMES OF MESANGIAL CELL PKC ISOZYME ACTIVATION
The activation of mesangial cell PKC, through either the direct effects of high glucose described above or the autocrine and paracrine action of vasoactive peptides such as angiotensin II and endothelin (ET)-1, results in the enhanced expression of TGF-␤ 1 and extracellular matrix proteins (54, 71) . The importance of individual PKC isozyme activation in the diabetic milieu initiating early diabetic nephropathy was first identified by Ishii et al. (34) . This group discovered that the compound LY-333531, which specifically inhibits PKC-␤ I and -␤ II , when administered orally to STZ-diabetic rats, not only prevents an elevated glomerular filtration rate, increased albumin excretion rate, and increased retinal circulation time but also overexpression of mRNA for glomerular TGF-␤ 1 and extracellular matrix proteins (39) . LY-333531 also prevents progressive mesangial expansion in the type 2 diabetic db/db mouse model (38) . Scivittaro et al. (57) have identified that proteins rich in intracellular advanced glycation end products selectively activate mesangial cell PKC-␤ II through a mechanism involving oxidative stress, implicating no requirement for DAG. Cohen et al. (7) have identified that glycated albumin stimulates mesangial cell PKC-␤ activity, which is linked to the increased expression of collagen IV. The exact role of PKC-␤ in the early pathogenesis of diabetic retinopathy and nephropathy is presently being investigated in human clinical trials using LY-333531.
Vasoactive peptides such as angiotensin II are expressed normally in small quantities to maintain hemodynamic stability and may contribute to glomerular autoregulation. In the diabetic state, enhanced expression of peptide growth factors by mesangial cells, e.g., ET-1 (27) , and other renal cells, e.g., angiotensin II (74), may contribute to the pathogenesis of diabetic nephropathy because mesangial cells constitutively express high-affinity receptors for these vasoactive peptides. Both ET-1 (14) and angiotensin II (Whiteside C, unpublished observations) stimulate mesangial cell PKC-␣, -␦, and -⑀. We have observed that the pattern of mesangial cell PKC-␦ and -⑀ translocation in response to ET-1 changes from cytosol-to-membrane distribution in normal glucose to cytosol-to-particulate (cytoskeleton/nucleus) in high glucose (18) , in keeping with our confocal immunofluorescence imaging data (76) . These findings suggest a change in compartmentalization and, possibly, the function of these PKC isozymes in the diabetic milieu.
Downstream of DAG-sensitive PKC isozymes is their activation of mitogen-activated protein kinases, particularly extracellular signal-regulated kinase (ERK)1/2, which are necessary for mesangial cell growth and enhanced gene expression, including growth factors and extracellular matrix proteins (17, 35) . In both mesangial cells cultured in high glucose (18, 25) and glomeruli isolated from STZ-diabetic rats (3), ERK1/2 protein expression is unchanged but its activity (basal) is significantly increased compared with normal-glucose controls and is PKC dependent. Isono et al. (35) identified that high-glucose-enhanced mesangial cell TGF-␤ 1 and extracellular matrix protein expression is mediated through ERK1/2. In cultured mesangial cells, high-glucose-enhanced ERK1/2 activity in response to ET-1 is entirely PKC dependent (18) . Hence, high glucose causes amplification of signaling through PKC pathways. Recently, we have reported that high-glucose-enhanced expression of collagen IV by mesangial cells, when stimulated with ET-1, requires the action of specific PKC isozymes (31) . The independent effect of each PKC isozyme was revealed by transient transfection of dominant negative cDNAs, which inhibit the action of individual PKC isozymes. ET-1-stimulated collagen IV expression is also dependent on the activation of ERK1/2. Using this dominant negative-transfection strategy, we demonstrated that ET-1 activation of ERK1/2 is necessary and dependent on PKC-␦, -⑀, and -. We also showed that PKC-␤ is necessary for ET-1 stimulation of mesangial cell collagen IV expression but that this is ERK1/2 independent (31). These data suggest that the PKC isozymes stimulated by ET-1 have hierarchical or redundant functions in the signaling cascades leading to collagen IV expression and that basal activities of PKC-␤ and -are required for the high-glucose-enhanced mesangial cell expression of this key extracellular matrix protein, contributing to diabetic glomerulosclerosis.
Mesangial cells exposed to high glucose for 24 h lose their normal contractile responsiveness to vasoactive peptides and demonstrate a cytoskeletal pattern of F-actin disassembly and depolymerization (13) . The lack of a mesangial cell contractile response in high glucose mimics the hypocontractility observed in afferent and, to a lesser extent, efferent glomerular arteriolar smooth muscle cells in the diabetic milieu (73) . The exact cellular mechanism linking high glucose to loss of normal contraction in response to vasoactive peptides or to arterial pressure in the afferent arteriole remains elusive. We recently reported that mesangial cell PKC-demonstrates increased membrane association and enhanced activity in high glucose after 24 h (13). Inhibition of PKC-with a cell-permeant, myristoylated PKC-peptide inhibitor restored the normal contractile response of cultured mesangial cells to stimuli such as ET-1 (13) and prevented mesangial cell F-actin disassembly. These are the first data to link the effects of high glucose causing mesangial cell hypocontractility and cytoskeletal dysfunction to a specific PKC isozyme. Further investigation is required to identify whether a similar mechanism causes glomerular arteriolar vascular smooth muscle cell dysfunction in high glucose.
SUMMARY AND FUTURE DIRECTIONS
In high glucose, mesangial cell PKC isozyme activity is enhanced both in the basal state and in response to vasoactive growth peptides. Increasing evidence supports a linkage between abnormal glucose metabolism through the polyol pathway and other mechanisms that generate reactive oxygen species and the increased activity of PKC isozymes in the diabetic state. PKC-␤ is a major pathogenic PKC isozyme contributing to early progressive diabetic nephropathy. Other PKC isozymes, including PKC-, may also be important. Future investigation will focus on elucidating the relevance of PKC isozymes in maintaining normal mesangial cell function and further delineating their contributions to high-glucose-mediated transformation of mesangial cells into a sclerotic phenotype. The development of specific PKC isozyme inhibitors, in addition to LY-333531, may prove useful for future targeted drug interventions in the treatment and prevention of diabetic nephropathy.
